Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Daniel P. Petrylak, Ronald de Wit, Kim N., Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Fléchon, Aristotelis Bamias,

The Lancet Oncology

Platinum-based TherapyUrologyGenitourinary CancerMedicineDocetaxel Versus PlaceboClinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyOverall Survival